Passive immunization with a human immunodeficiency virus type 1- neutralizing monoclonal antibody in Hu-PBL-SCID mice: Isolation of a neutralization escape variant

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 889-897

  Andrus, Linda ^a   Prince, Alfred M ^b   Bernal, Iscela ^b   McCormack, Patricia ^b   Lee, Dong Hun ^b   Gorny, Miroslaw K ^b   Zolla Pazner, Susan ^b  

^a NEW YORK BLOOD CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

EID: 0031968725     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515251     Document Type: Article

References (15)

1. Orenstein WA, Heymann DL, Ellis RJ, et al. Prophylaxis of varicella in high risk children: dose response effect of zoster immune globulin. J Pediatr 1981;98:368-73.
2. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
3. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-54.
4. Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993;168:298-305.
5. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double blind randomized study based on transfusions of plasma rich in human immunodeficiency virus-1 antibodies versus transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;92: 1195-9.
6. Hinkula J, Bratt G, Gilljam G, et al. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr 1994;7:940-51.
7. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991;7:971-3.
8. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-30.
9. Gomy MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150:635-43.
10. Corny MK, Conley AJ, Karwowska S, el al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-42.
11. Conley AJ, Gomy MK, Kessler JA, et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
12. Prince AM, Horowitz B, Baker L, et al. Failure of an HIV immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci USA 1988;85:6944-8.
13. Prince AM, Saunders A, Pascual D, et al. Mechanisms for the failure of passively administered neutralizing antibodies to protect against HIV challenge in the chimpanzee model. In: Channock RM, Lemer RA, Brown F, Ginsberg H, eds. Vaccines 89. New York: Cold Spring Harbor Laboratory Press, 1989:195-9.
14. Epstein J, Kulken C, Blumberg BM, et al. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology 1991;180:583-90.
15. Holmes DS, Quigley M. A rapid boiling method for the preparation of bacterial plasmids. Anal Biochem 1981;114:193-7.